Segment and Geographic Information - Reconciliation of Reportable Segment Operating Income (Loss) to Corresponding Consolidated Amounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2021
Segment Reporting Information [Line Items]
Total revenue	$ 665,072	$ 555,498	$ 513,703
Amortization of other intangible assets	48,400	32,300	37,400
Restructuring and restructuring related charges	4,577	712	13,749
Contingent consideration - fair value adjustments	(18,549)	600
Merger and acquisition costs and costs related to share repurchase	13,842	17,329	20,662
Total operating (loss) income	(73,126)	(24,735)	(31,089)
Interest income	43,735	20,286	632
Interest expense		(4,589)	(2,037)
Loss on extinguishment of debt		(632)
Other, net	(1,042)	(266)	(16,475)
Loss before income taxes	(30,433)	(9,936)	(48,969)
Acquired Intangible Assets
Segment Reporting Information [Line Items]
Amortization of other intangible assets	28,207	24,965	29,299
Life Sciences Products
Segment Reporting Information [Line Items]
Total revenue	305,184	199,230	199,606
Life Sciences Services
Segment Reporting Information [Line Items]
Total revenue	359,888	356,268	314,097
Operating Segments
Segment Reporting Information [Line Items]
Total operating (loss) income	(45,043)	21,817	45,753
Operating Segments | Life Sciences Products
Segment Reporting Information [Line Items]
Total operating (loss) income	(30,321)	11,033	23,094
Operating Segments | Life Sciences Services
Segment Reporting Information [Line Items]
Total operating (loss) income	(14,722)	10,784	22,659
Corporate, Non-Segment
Segment Reporting Information [Line Items]
Other unallocated corporate expense	$ 6	$ 2,946	$ 13,132